Cargando…

Angiotensin Converting Enzyme‐2 Therapy Improves Liver Fibrosis and Glycemic Control in Diabetic Mice With Fatty Liver

Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease and is frequently associated with type 2 diabetes. However, there is no specific medical therapy to treat this condition. Angiotensin‐converting enzyme 2 (ACE2) of the protective renin angiotensin system gener...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rajapaksha, Indu G., Gunarathne, Lakmie S., Asadi, Khashayar, Laybutt, Ross, Andrikopoulous, Sof, Alexander, Ian E., Watt, Mathew J., Angus, Peter W., Herath, Chandana B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035567/ https://www.ncbi.nlm.nih.gov/pubmed/34951153 http://dx.doi.org/10.1002/hep4.1884

Ejemplares similares

Liver‐Targeted Angiotensin Converting Enzyme 2 Therapy Inhibits Chronic Biliary Fibrosis in Multiple Drug‐Resistant Gene 2‐Knockout Mice
por: Rajapaksha, Indu G., et al.
Publicado: (2019)

Update on New Aspects of the Renin-Angiotensin System in Hepatic Fibrosis and Portal Hypertension: Implications for Novel Therapeutic Options
por: Rajapaksha, Indu G., et al.
Publicado: (2021)

Cirrhotic portal hypertension: From pathophysiology to novel therapeutics
por: Gunarathne, Lakmie S, et al.
Publicado: (2020)

Mas‐related G protein‐coupled receptor type D antagonism improves portal hypertension in cirrhotic rats
por: Gunarathne, Lakmie S., et al.
Publicado: (2022)

Blockade of Mas Receptor or Mas-Related G-Protein Coupled Receptor Type D Reduces Portal Pressure in Cirrhotic but Not in Non-cirrhotic Portal Hypertensive Rats
por: Gunarathne, Lakmie S., et al.
Publicado: (2019)

The small molecule drug diminazene aceturate inhibits liver injury and biliary fibrosis in mice
por: Rajapaksha, Indu G., et al.
Publicado: (2018)

Upregulation of hepatic angiotensin-converting enzyme 2 (ACE2) and angiotensin-(1–7) levels in experimental biliary fibrosis()
por: Herath, Chandana B., et al.
Publicado: (2007)

Current therapies and novel approaches for biliary diseases
por: Rajapaksha, Indu G, et al.
Publicado: (2019)

Changes in the renin angiotensin system during the development of colorectal cancer liver metastases
por: Neo, Jaclyn H, et al.
Publicado: (2010)

Serum levels of angiotensin converting enzyme as a biomarker of liver fibrosis
por: Miranda, Aline Silva, et al.
Publicado: (2017)

Angiotensin Converting Enzymes
por: Wong, Marty K.S.
Publicado: (2016)

Angiotensin converting enzyme
por: Wong, Marty Kwok-Shing
Publicado: (2021)

Effects of Angiotensin Converting Enzyme Inhibitors on Liver Fibrosis in HIV and Hepatitis C Coinfection
por: Reese, Lindsey J., et al.
Publicado: (2012)

Angiotensin-Converting Enzyme-2
por: Clarke, Nicola E., et al.
Publicado: (2013)

Angiotensin-converting enzyme activity and inhibition in dogs with cardiac disease and an angiotensin-converting enzyme polymorphism
por: Meurs, Kathryn M, et al.
Publicado: (2017)

Dietary Potassium Downregulates Angiotensin-I Converting Enzyme, Renin, and Angiotensin Converting Enzyme 2
por: Vio, Carlos P., et al.
Publicado: (2020)

Angiotensin-Converting Enzyme 2 and Antihypertensives (Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors) in Coronavirus Disease 2019
por: Sanchis-Gomar, Fabian, et al.
Publicado: (2020)

Dietary advanced glycation end-products aggravate non-alcoholic fatty liver disease
por: Leung, Christopher, et al.
Publicado: (2016)

Effect of Angiotensin-Converting Enzyme Inhibitor, Lisinopril on Morphological and Biochemical Aspects of Fibrotic Liver Regeneration
por: Ambreen, Aysha, et al.
Publicado: (2016)

Angiotensin-converting enzyme 2 improves hepatic insulin resistance by regulating GABAergic signaling in the liver
por: Chen, Qi, et al.
Publicado: (2022)

Angiotensin-Converting Enzyme 2 and the Resolution of Inflammation: In Support of Continuation of Prescribed Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers
por: Gersh, Felice L.
Publicado: (2020)

Angiotensin-Converting Enzyme Inhibitors and Angioedema
por: Sánchez-Borges, Mario, et al.
Publicado: (2010)

Angiotensin-converting Enzyme Genetic Polymorphism
por: Wiwanitkit, Somsri, et al.
Publicado: (2014)

Renal Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Patients with Liver Cirrhosis: A Nationwide Cohort Study
por: Hsu, Wei-Fan, et al.
Publicado: (2019)

Hemodynamic Effects of the Non-Peptidic Angiotensin-(1-7) Agonist AVE0991 in Liver Cirrhosis
por: Klein, Sabine, et al.
Publicado: (2015)

In reply—Angiotensin-Converting Enzyme 2 and the Resolution of Inflammation: In Support of Continuation of Prescribed Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers
por: Sanchis-Gomar, Fabian, et al.
Publicado: (2020)

Renin‐angiotensin aldosterone profile before and after angiotensin‐converting enzyme‐inhibitor administration in dogs with angiotensin‐converting enzyme gene polymorphism
por: Adin, Darcy, et al.
Publicado: (2020)

Loss of angiotensin converting enzyme II (ACE2) accelerates the development of liver injury induced by thioacetamide
por: Wu, Hsi-Tien, et al.
Publicado: (2017)

Angiotensin-converting enzyme 2 improves liver fibrosis in mice by regulating autophagy of hepatic stellate cells
por: Wu, Ying, et al.
Publicado: (2023)

Intrarenal Distributions and Changes of Angiotensin-Converting Enzyme and Angiotensin-Converting Enzyme 2 in Feline and Canine Chronic Kidney Disease
por: MITANI, Sawane, et al.
Publicado: (2013)

Angiotensin-Converting Enzyme 2: The First Decade
por: Clarke, Nicola E., et al.
Publicado: (2012)

Angiotensin-I-converting enzyme and its relatives
por: Riordan, James F
Publicado: (2003)

Serum Angiotensin Converting Enzyme in Pemphigus Vulgaris
por: Robati, Reza M, et al.
Publicado: (2014)

Angiotensin Converting Enzyme Activity in Alopecia Areata
por: Namazi, Mohammad Reza, et al.
Publicado: (2014)

Angiotensin-converting enzyme 2 in lung diseases
por: Kuba, Keiji, et al.
Publicado: (2006)

Angiotensin converting enzyme polymorphism and ischemic stroke
por: Salem, Gelan M., et al.
Publicado: (2020)

Angiotensin-converting-enzyme inhibitor–induced angioedema
por: Quickfall, Danica, et al.
Publicado: (2021)

Interaction Between Angiotensin-Converting Enzyme Gene Insertion/Deletion Polymorphism and Angiotensin-Converting Enzyme Inhibition on Survival in Hemodialyzed Patients
por: Kiss, István, et al.
Publicado: (2014)

Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Angiotensin-Converting Enzyme 2 Levels: A Comprehensive Analysis Based on Animal Studies
por: Kriszta, Gábor, et al.
Publicado: (2021)

Activation of the Alternate Renin-Angiotensin System Correlates with the Clinical Status in Human Cirrhosis and Corrects Post Liver Transplantation
por: Casey, Stephen, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_5n90vpqlbutmd4t96948t4gnkt